Cargando…

Efficacy of compound traditional Chinese medicine oil in alleviating regorafenib-induced hand-foot skin reaction

OBJECTIVE: Regofinib is a novel, oral, anticancer target which greatly improves survival of patients with colorectal cancer. However, it causes 47%–71% patients occur hand–foot skin reaction (HFSR), which affects the quality of life (QOL) or prognosis of patients. However targeted and effective meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Liyan, Cai, Jieyuan, Sun, Hong, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072176/
https://www.ncbi.nlm.nih.gov/pubmed/35529418
http://dx.doi.org/10.1016/j.apjon.2021.10.002
Descripción
Sumario:OBJECTIVE: Regofinib is a novel, oral, anticancer target which greatly improves survival of patients with colorectal cancer. However, it causes 47%–71% patients occur hand–foot skin reaction (HFSR), which affects the quality of life (QOL) or prognosis of patients. However targeted and effective methods are rare. The study attempted to test the efficacy of the compound traditional Chinese medicine (CTCM) oil in relieving HFSR and improving the QOL. METHODS: The present study was conducted in 85 patients with metastatic colorectal cancer presenting with HFSR from July 2019 to June 2020. These patients were divided into the control group (n = 42) and the intervention group (n = 43). The HFSR in the control group was managed using traditional methods, whereas that in the intervention group was treated with a CTCM oil comprising five selected herbs. This oil functions by regulating the vascular endothelial growth factor receptor, inflammatory factors, and immune status, and it was provided to the patients to apply externally twice a day. HFSR remission and QOL were evaluated in both groups after 2 weeks of intervention. RESULTS: The post-intervention HFSR remission rate was significantly higher in the intervention group than in the control group (65.1% vs. 16.7%) (P < 0.01). The overall QOL, physical function, social function, and emotional function of the patients in the intervention group were significantly improved (P < 0.05), whereas the pain symptoms were more significantly improved (P < 0.01). CONCLUSIONS: The CTCM oil can effectively alleviate HFSR and improve the QOL of patients using regorafenib.